Funding the cash offer

Advanced Medical Solutions (LSE:AMS), the UK maker of surgical sealants, sutures and wound care products, remains in an Offer Period following the board-backed cash offer from US adhesives group H.B. Fuller announced on 25 June 2026. In the 24 hours to early on 3 November 2026 there was no new company announcement on the deal, although there was a steady flow of Form 8.3 and 8.5 dealing disclosures on 29 and 30 October, which are routine during an offer period.

The development most relevant to deliverability in recent weeks has come from the bidder's side. On 8 October 2026, H.B. Fuller said it had priced US$850m of senior unsecured notes due 2034, carrying a coupon of 7.625% and issued at 100% of principal, with closing expected on or about 21 October 2026.

What the financing documents say

According to H.B. Fuller's announcement and an earlier filing with the US Securities and Exchange Commission dated 6 October, which described the offering at launch as US$950m, the proceeds, together with other cash and borrowings, are intended to fund the purchase price for AMS and related fees and expenses, including certain AMS net debt. They will also be used to repay borrowings under an existing Credit agreement and to refinance its 4.000% notes due February 2027.

The notes contain a special mandatory Redemption clause. If the Acquisition is not completed by an outside date of 25 June 2027, or if H.B. Fuller notifies the Trustee that the co-operation agreement with AMS has been terminated and the deal will not proceed by that date, it must redeem US$450m of the notes at 100% of the issue price plus accrued interest. The outside date can be extended, but not beyond the first anniversary of the notes' issue.

Why it matters for AMS shareholders

The terms announced in June offered 285p in cash per AMS (LSE:AMS) share, which valued the company at about £715m. AMS shareholders approved the proposal at meetings held on 12 August 2026, and H.B. Fuller said then that it expected the transaction to close by the end of calendar 2026, subject to the remaining conditions in the transaction documents.

Our interpretation is that raising committed long-term Debt reduces one source of execution risk, namely the bidder's ability to pay. The redemption clause, which is standard in acquisition financings, also shows that the bidder has planned for the possibility that the deal does not complete. At the close of the 2 November session, AMS shares were about 282.5p.

Risks and remaining conditions

Completion still depends on satisfying or waiving the outstanding conditions, which the August release did not specify, and on the court sanction stage typical of a scheme of arrangement. Regulatory reviews can sometimes take longer than planned. If the deal lapsed, AMS would continue as an independent listed company. In a half-year trading update in July 2026, AMS reported first-half Revenue of about £115.2m, up about 4%, citing some orders shipped in early July and a planned de-stocking linked to expanding direct sales in Europe; it said it remained confident of full-year EBITDA in line with market expectations, a statement treated under the Takeover Code as an ordinary course profit forecast.

Shareholders should also note that H.B. Fuller's Leverage will rise to fund the deal, a matter for its own investors rather than a condition of the offer.

What to watch

The next steps are announcements on the satisfaction of remaining conditions, a court sanction hearing date and the expected effective date of the scheme, after which AMS shares would be cancelled from trading on AIM. Until those are announced, the end-2026 closing expectation and the June 2027 outside date frame the timetable.